Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

By Kai Chang, I. Pastan. 1996

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Mesothelin-targeted CAR-T cell therapy for solid tumors (2020, background): “(MPF) and a ~ 40-kDa GPI-anchored mesothelin protein, bound on the cell surface [5,39,40] (Figure 1).”
Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies (2013, background): “Mesothelin is a tumor-associated antigen that is overexpressed in the majority of malignant pleural mesotheliomas (MPM), pancreatic cancers, ovarian cancers, and some lung cancers (9, 10).”
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (2013, background): “The tumor differentiation antigen mesothelin is an attractive candidate for targeted therapy of mesothelioma because it is highly expressed on tumor cells and its expression in normal tissues is limited to mesothelial cells lining the pleura, peritoneum, and pericardium (5, 6).”
Application of Mesothelin Immunostaining in Tumor Diagnosis (2003, background): “Using this antibody, mesothelin overexpression was reported in mesotheliomas,(2) nonmucinous carcinomas of the ovary,(5) and certain squamous carcinomas.(6) In 1992, Chang et al(2) reported mesothelin expression in all 15 epithelioid mesotheliomas, but in none of 23 lung adenocarcinomas, and conclud”